Clinical Trials Sponsored by Genome Medical

Total 57328 results

Second Genome

Terminated

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States
Genome & Company

Not yet recruiting

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Korea, Republic of
Human Genome Sciences Inc.

Completed

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Germany, Hungary, Romania
Human Genome Sciences Inc.

Completed

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

United States, Canada
Human Genome Sciences Inc.

Completed

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

HIV Infections

United States
Human Genome Sciences Inc.

Completed

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States
University Medical Center Groningen
Human Genome Sciences Inc.

Completed

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

Advanced Cervical Cancer

Netherlands
Javelin Medical
Genae

Active, not recruiting

Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants (CAPTURE2)

Stroke | Atrial Fibrillation

Germany, Spain, Belgium, Czechia, Greece, Hungary, Israel, Poland
Human Genome Sciences Inc.

Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Canada, Australia, Israel, Germany, Czech Republic, France, Poland, Romania
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Human Genome Sciences Inc.

Terminated

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

Rheumatoid Arthritis

United States, Poland
Human Genome Sciences Inc.

Completed

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Human Genome Sciences Inc.

Completed

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

Chronic Hepatitis C

Canada
Human Genome Sciences Inc.

Withdrawn

Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis

Ulcerative Colitis
HemoShear Therapeutics
Prometrika, LLC; AllStripes Research Inc.; Genome Medical

Terminated

Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia (JUMP)

Propionic Acidemia | Methylmalonic Acidemia

United States, Canada, United Kingdom
Human Genome Sciences Inc.

Completed

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Human Genome Sciences Inc.

Completed

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Hepatitis C

United States
Human Genome Sciences Inc.

Terminated

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Lymphoid Malignancies

United States, United Kingdom
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)

Systemic Lupus Erythematosus

United States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-52)

Systemic Lupus Erythematosus

Hong Kong, Taiwan, Korea, Republic of, India, Chile, Argentina, Philippines, Colombia, Brazil, Romania, Australia, Peru, Russian Federation
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76

Systemic Lupus Erythematosus
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
Eurofins Genoma

Enrolling by invitation

Evaluation of Genetic Signature in Endometriosis Disease by Non Invasive Sampling (niEndometriosi)

Endometriosis | Hypofertility

Italy
Human Genome Sciences Inc.
GlaxoSmithKline

Terminated

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Mexico
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer

Pancreatic Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Pancreatic Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Iwate Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma
Iwate Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

Bladder Cancer

Japan
University of British Columbia
Genome British Columbia; Genome Canada; Dynacare Laboratories, Inc.

Recruiting

Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System

Adverse Drug Reaction (ADR)

Canada
CHU de Quebec-Universite Laval
Laval University; Genome Canada; Genome Quebec; CERSSPL

Completed

Evaluating an Online Training Program on Shared Decision-making in Prenatal Screening

Shared Decision Making

Canada
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

Systemic Lupus Erythematosus

Korea, Republic of, Japan
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Systemic Lupus Erythematosus

Korea, Republic of, China, Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)

Pancreatic Cancer

Japan
Iwate Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer

Bladder Cancer

Japan
Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer

Pancreatic Cancer

Japan
Prenome

Recruiting

OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study

Pregnancy Complications | Pregnancy Related | Gestational Diabetes | Risk Reduction | Genetic Predisposition

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR); Laval University; Genome British... and other collaborators

Completed

Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (PEGASUS)

Trisomy 21 | Trisomy 18 | Trisomy 13

Canada
Iwate Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Novel Peptide Vaccination for Patients With Advanced Prostate Cancer

Prostate Cancer

Japan
Wakayama Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Andrew Penn
Heart and Stroke Foundation of Canada; Genome British Columbia; Bruker Daltonics and other collaborators

Completed

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

TIA

Canada

Clinical Trials Sponsored by Genome Medical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations